×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ENLV – enlivex therapeutics ltd. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ENLV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/26
08:30 am
enlv
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
Medium
Report
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
3/25
08:30 am
enlv
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
Medium
Report
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
3/24
08:30 am
enlv
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
Low
Report
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
3/23
08:00 am
enlv
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Low
Report
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
2/10
08:00 am
enlv
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
Medium
Report
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
1/26
08:00 am
enlv
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
High
Report
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
1/23
06:51 pm
enlv
RAIN Hits All-Time High After WhiteBIT Listing, Gains 17% in 24 Hours [Yahoo! Finance]
High
Report
RAIN Hits All-Time High After WhiteBIT Listing, Gains 17% in 24 Hours [Yahoo! Finance]
1/23
08:00 am
enlv
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
Medium
Report
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/26
08:32 am
enlv
Form 6-K Enlivex Ltd. For: Mar 26
Medium
Report
Form 6-K Enlivex Ltd. For: Mar 26
3/25
08:40 am
enlv
Form 20-F Enlivex Ltd. For: Dec 31
Medium
Report
Form 20-F Enlivex Ltd. For: Dec 31
3/25
08:31 am
enlv
Form 6-K Enlivex Ltd. For: Mar 25
Medium
Report
Form 6-K Enlivex Ltd. For: Mar 25
3/24
08:35 am
enlv
Form 6-K Enlivex Ltd. For: Mar 24
Low
Report
Form 6-K Enlivex Ltd. For: Mar 24
3/23
08:02 am
enlv
Form 6-K Enlivex Ltd. For: Mar 23
Low
Report
Form 6-K Enlivex Ltd. For: Mar 23
3/18
07:15 am
enlv
Form 3 Enlivex Ltd. For: Mar 18 Filed by: Hershkovitz Oren
Low
Report
Form 3 Enlivex Ltd. For: Mar 18 Filed by: Hershkovitz Oren
3/18
07:14 am
enlv
Form 3 Enlivex Ltd. For: Mar 18 Filed by: Shlosberger Shachar
Low
Report
Form 3 Enlivex Ltd. For: Mar 18 Filed by: Shlosberger Shachar
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/16
Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange
13.1%
3/13 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.50 price target on the stock. 10.8%
11/14 Form 6-K Enlivex Therapeutics For: Nov 14 10.5%
6/24 Form EFFECT Enlivex Therapeutics 9.2%
3/20 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock. 9.0%
9/23 First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference 7.2%
11/20 Form 424B5 Enlivex Therapeutics 6.9%
3/9 Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment 5.6%
11/18 Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis 5.3%
7/10 Form 424B3 Enlivex Therapeutics 4.5%
3/13 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.50 price target on the stock. 10.8%
11/14 Form 6-K Enlivex Therapeutics For: Nov 14 10.5%
6/24 Form EFFECT Enlivex Therapeutics 9.2%
3/20 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock. 9.0%
9/23 First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference 7.2%
11/20 Form 424B5 Enlivex Therapeutics 6.9%
3/9 Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment 5.6%
11/18 Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis 5.3%
7/10 Form 424B3 Enlivex Therapeutics 4.5%
TOP News Decliners
3/18
Form 6-K Enlivex Therapeutics For: Mar 18
-29.3%
2/24 Enlivex's stock rockets after plans to boost in capacity for treatment of COVID-19-like symptoms [MarketWatch] -26.0%
10/7 Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization’s 2019 Cell Death in Immunity and Inflammation Workshop -19.3%
10/8 European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment -12.0%
3/5 Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering -9.7%
3/26 Greenberg Traurig Assists Enlivex Therapeutics with $24.75 Million in Financing -9.6%
10/10 Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies -9.4%
6/6 Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients -8.3%
1/23 Form 20-F/A Enlivex Therapeutics For: Dec 31 -8.2%
3/3 Form 424B5 Enlivex Therapeutics -6.5%
2/24 Enlivex's stock rockets after plans to boost in capacity for treatment of COVID-19-like symptoms [MarketWatch] -26.0%
10/7 Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization’s 2019 Cell Death in Immunity and Inflammation Workshop -19.3%
10/8 European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment -12.0%
3/5 Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering -9.7%
3/26 Greenberg Traurig Assists Enlivex Therapeutics with $24.75 Million in Financing -9.6%
10/10 Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies -9.4%
6/6 Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients -8.3%
1/23 Form 20-F/A Enlivex Therapeutics For: Dec 31 -8.2%
3/3 Form 424B5 Enlivex Therapeutics -6.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: